Phase II study of irinotecan (CPT‐11) as salvage therapy for advanced nasopharyngeal carcinoma

Abstract

Results from this trial suggest that irinotecan is an active salvage agent with modest toxicity in patients with advanced NPC who are refractory to platinum/taxane-based chemotherapy. Studies combining irinotecan with other active agents in the first-line setting are warranted.